Correction: Cost of Anti-CD38 Monoclonal Antibodies in Combination With Bortezomib, Lenalidomide and Dexamethasone for the Frontline Treatment of Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma in the US.

IF 2.3 Q2 ECONOMICS

Journal of Health Economics and Outcomes Research Pub Date : 2025-08-12 eCollection Date: 2025-01-01 DOI:10.36469/001c.143106

Niodita Gupta-Werner, Vipin Khare, Brian Macomson, Rohan Medhekar

引用次数: 0

Abstract

[This corrects the article DOI: 10.36469/001c.141714.].

查看原文本刊更多论文

校正：在美国，抗cd38单克隆抗体联合硼替佐米、来那度胺和地塞米松一线治疗新诊断的不适合移植的多发性骨髓瘤患者的成本

[这更正了文章DOI: 10.36469/ 001c141714 .]。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Health Economics and Outcomes Research Medicine-Health Policy

CiteScore

3.00

自引率

0.00%

发文量

审稿时长

10 weeks